AVKARE Inc. is recalling 6,326 bottles of Oxybutynin Chloride Extended-Release Tablets USP (10 mg), used to treat overactive bladder. The recall was initiated because the tablets failed to meet dissolution specifications, which means the medication may not release properly into the body. This could result in the drug being less effective or not working as intended for patients.
If the medication fails to dissolve correctly, the patient may not receive the intended therapeutic dose, potentially leading to a return or worsening of overactive bladder symptoms. There have been no reported injuries or adverse events related to this recall at this time.
Contact healthcare provider and return product for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.